MSD’s Keytruda wins expanded FDA combo approval in cervical cancer
Pharmaceutical Technology
JANUARY 15, 2024
MSD’s blockbuster immunotherapy, set to lose patent protection in 2028, secures third FDA approval in cervical cancer.
Pharmaceutical Technology
JANUARY 15, 2024
MSD’s blockbuster immunotherapy, set to lose patent protection in 2028, secures third FDA approval in cervical cancer.
BioPharma Reporter
JANUARY 15, 2024
CellVoyant, an AI-first biotechnology spin-out from the University of Bristol accelerating the development of novel cell therapies, has announced a Â7.6 million seed round.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 15, 2024
The acquired programme consists of antibiotics against gram-negative bacteria, including multidrug-resistant strains.
Pharmaceutical Commerce
JANUARY 15, 2024
FDA approves Keytruda (pembrolizumab) combined with chemoradiation for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer, which is the 39th overall approved indication for the drug in the United States.
Pharmaceutical Technology
JANUARY 15, 2024
If new treatments are shown to maintain weight loss, they will become game changers within the obesity space.
pharmaphorum
JANUARY 15, 2024
Speculation about a takeover play for Cytokinetics isn’t going away, with Amgen the latest company to be linked to the company and its highly-anticipated cardiovascular drug aficamten.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
JANUARY 15, 2024
Researchers at the University of Cambridge and Pfizer have developed an AI-powered approach to make it easier to design and make pharma molecules
Pharmaceutical Technology
JANUARY 15, 2024
PCM Trials, a Denver, USA based leader in providing mobile research nurses for decentralized clinical trials, today announced the acquisition of Clinical Trial Service (CTS).
Drug Discovery World
JANUARY 15, 2024
Merck (MSD), through a subsidiary, has agreed to acquire immunotherapy company Harpoon Therapeutics for $680 million. The acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumours. The announcement follows the news that Merck agreed a deal with Inspirna for colorectal cancer drug ompenaclid (RGX-202).
XTalks
JANUARY 15, 2024
The field of clinical research will witness significant advancements in 2024. From the continuing trend of the rapid adoption of AI tools to the growing use of real-world evidence (RWE) in regulatory decision-making and a focus on enhancing data integrity, find out how clinical trials will evolve in 2024 to shape the future of medical research. Read on to learn about the top 10 clinical trial trends for 2024, and be sure to explore and join upcoming webinars about clinical trials at Xtalks. 1.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
JANUARY 15, 2024
MSD’s Keytruda has been cleared by the FDA as the first PD-1 inhibitor for newly diagnosed cervical cancer patients with less severe disease
JAMA Internal Medicine
JANUARY 15, 2024
This cohort study examines the whether there were changes in opioid prescribing and opioid-related health outcomes after implementation of British Columbia’s Safer Opioid Supply policy.
pharmaphorum
JANUARY 15, 2024
Santhera’s new treatment for Duchenne muscular dystrophy Agamree has been launched in its first market, Germany, following its EU approval last month.
Outsourcing Pharma
JANUARY 15, 2024
Access to opioids such as fentanyl can lead to abuse but now two companies have signed an agreement to reduce the abuse potential while making sure they are still accessible to those who need them.
pharmaphorum
JANUARY 15, 2024
Germany’s IG BCE trade union has pushed back against any break-up of Bayer, claiming it could put thousands of domestic jobs at risk
Pharma Times
JANUARY 15, 2024
CellVoyant’s platform combines AI with live cell imaging
pharmaphorum
JANUARY 15, 2024
True innovation in life sciences is only possible through a connected, pan-European approach Mike.
Pharma Times
JANUARY 15, 2024
Companies collaborate to launch walk-in pain clinic
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Outsourcing Pharma
JANUARY 15, 2024
Cormica Bradford, a division of Cormica says it is proud to announce a significant expansion of its laboratory capabilities.
XTalks
JANUARY 15, 2024
As far as condiments go, few brands have managed to capture the hearts and taste buds of food enthusiasts quite like TRUFF. Known for infusing the luxury of truffles into everyday pantry staples, TRUFF recently unveiled its newest creation: the TRUFF Jalapeño Lime Hot Sauce. This vibrant green sauce, distinct in both flavor and color, marks a bold new chapter in the company’s innovative journey.
Outsourcing Pharma
JANUARY 15, 2024
SGD Pharma has announced its goal to become the global market leader in primary pharmaceutical glass packaging.
pharmaphorum
JANUARY 15, 2024
Orion buys stake in LegoChem amid pivot to cancer and pain Phil.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Outsourcing Pharma
JANUARY 15, 2024
Cormica Bradford, a division of Cormica says it is proud to announce a significant expansion of its laboratory capabilities.
Drug Patent Watch
JANUARY 15, 2024
Annual Drug Patent Expirations for PROLENSA Prolensa is a drug marketed by Bausch And Lomb and is included in one NDA. It is available from two suppliers. There are nine… The post New patent expiration for Bausch And drug PROLENSA appeared first on DrugPatentWatch - Make Better Decisions.
Outsourcing Pharma
JANUARY 15, 2024
Access to opioids such as fentanyl can lead to abuse but now two companies have signed an agreement to reduce the abuse potential while making sure they are still accessible to those who need them.
Drug Patent Watch
JANUARY 15, 2024
Annual Drug Patent Expirations for IGALMI Igalmi is a drug marketed by Bioxcel and is included in one NDA. It is available from one supplier. There are six patents protecting… The post New patent for Bioxcel drug IGALMI appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Discovery World
JANUARY 15, 2024
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week has seen a number of significant discoveries by researchers in academic institutions, in some cases in partnership with industry, emphasising the important role universities play in early-stage drug discovery.
Drug Patent Watch
JANUARY 15, 2024
Annual Drug Patent Expirations for LAZANDA Lazanda is a drug marketed by Btcp Pharma and is included in one NDA. There are five patents protecting this drug. This drug has… The post New patent expiration for Btcp Pharma drug LAZANDA appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 15, 2024
Artificial intelligence (AI) is transforming the healthcare industry, particularly in decision-making and therapeutic advancements. Learn how AI will revolutionise healthcare and impact future decision-making processes in this informative article.
Drug Patent Watch
JANUARY 15, 2024
Annual Drug Patent Expirations for ORGOVYX Orgovyx is a drug marketed by Sumitomo Pharma and is included in one NDA. It is available from one supplier. There are eight patents… The post New patent for Sumitomo Pharma drug ORGOVYX appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Let's personalize your content